Description of Collaborative Activity: |
The Filovirus Animal Non-Clinical Group (FANG) focuses on the advanced development of Filovirus Medical Countermeasures (MCM), both vaccines and therapeutics. The FANG will focus on the product development tools and other interagency product development (PD) issues relevant to Food and Drug Administration approval of filovirus MCM. The Portfolio Advisory Committee (PAC), as a standing interagency working group, oversees the FANG. The FANG will develop strategies to address broadly applicable and interagency product development issues relevant to licensure of filovirus MCM. The FANG will develop consensus recommendations to facilitate standardization of reagents, methods, and procedures across multiple agencies and laboratories. |
